Vriens, Kim
Christen, Stefan
Parik, Sweta
Broekaert, Dorien
Yoshinaga, Kazuaki
Talebi, Ali
Dehairs, Jonas
Escalona-Noguero, Carmen
Schmieder, Roberta
Cornfield, Thomas
Charlton, Catriona
Romero-Pérez, Laura
Rossi, Matteo
Rinaldi, Gianmarco
Orth, Martin F.
Boon, Ruben
Kerstens, Axelle
Kwan, Suet Ying
Faubert, Brandon
Méndez-Lucas, Andrés
Kopitz, Charlotte C.
Chen, Ting
Fernandez-Garcia, Juan
Duarte, João A. G.
Schmitz, Arndt A.
Steigemann, Patrick
Najimi, Mustapha
Hägebarth, Andrea
Van Ginderachter, Jo A.
Sokal, Etienne
Gotoh, Naohiro
Wong, Kwok-Kin
Verfaillie, Catherine
Derua, Rita
Munck, Sebastian
Yuneva, Mariia
Beretta, Laura
DeBerardinis, Ralph J.
Swinnen, Johannes V.
Hodson, Leanne
Cassiman, David
Verslype, Chris
Christian, Sven
Grünewald, Sylvia
Grünewald, Thomas G. P.
Fendt, Sarah-Maria
Article History
Received: 8 December 2017
Accepted: 20 December 2018
First Online: 6 February 2019
Competing interests
: A.H., C.C.K., A.S., P.S., S. Christian and S.G. have competing interests as employees of Bayer AG. K.-K.W. is a founder and equity holder of G1 Therapeutics and he has Consulting/Sponsored Research Agreements with AstraZeneca, Janssen, Pfizer, Array, Novartis, Merck, Takeda, Ono, Targimmune and BMS. S.-M.F. has received research funding from Bayer AG and Merck.